



Supplementary Figure 2. Remdesivir treatment results in sustained levels of pro-inflammatory IP-10 in intubated COVID-19 patients. T_H1 -associated immune mediator IP-10 levels in plasma before and one-week after RDV treatment in non-intubated responders ($n=21$, median 9 and 16 days post-illness onset (PIO), respectively) and intubated non-responders ($n=6$, median 7 and 13 days PIO, respectively), and matched timepoint 1 and 2 in non-RDV-treated non-intubated ($n=17$, median 10 and 16 days PIO, respectively) and intubated ($n=10$, median 6 and 12 days PIO, respectively) controls. Statistical analyses were performed with Wilcoxon matched-pairs signed rank test when comparing between timepoints, and Mann Whitney U test when comparing across groups ($*P<0.05$; $**P<0.01$). Immune mediator levels for healthy controls ($n=23$) are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of Limit of Quantification (LOQ).